home technology applications about us news
deltaDOT HPCE Analytical instruments offers dramatically improved discovery power in  comparison to other conventional CE systems without the use of molecular labels. This is  achieved by the combination of substantially enhanced resolution, sensitivity and quantification  power of the instrument, along with the digital output of data delivered as clearly resolved  separations. The system has proven capability in almost all modes of CE. It allows analyte  molecular weight and concentration to be assigned and absolute measurements can be  performed using calibrating markers. Supplied with the instrument is a powerful customized  suite of data handling and analysis tools.  
deltaDOT HPCE instruments 
UV light is directed from the source via filters and optical components at the capillary window.  The detector assembly contains a photodiode array of 512 detection points.  
Optical Rail 
Capillary block 
For most electrophoretic separations a fused silica capillary coated with polyimide on the  outside is used. The separation lengths can be set from 20 cm to 70 cm by selecting the  appropriate route in the capillary block.  
Data Analysis 
The data analysis of biomolecules performed using the deltaDOT HPCE LFII® system is  enabled by proprietary Equiphase Vertexing Algorithm (EVA) and Generalised Separation  Transform (GST) algorithms. GST is a method of combining the data from the multiple pixels in  a natural way which preserves the peak shape information of the electropherograms while at  the same time maximising the signal-to-noise ratio. A factor of 10 increase in signal-to-noise  using GST as compared to using single point detection, is typically observed 
13 October 2017 deltaDOT continues with Technology partnership publication (www.ttp.com)  The TTP Journal of Technology and Business Innovation provides technical insight into UK  advanced scientific businesses. New articles are now available on Water Ionic Analysis (...more)  and Nicotine Analysis (...more).  8 September 2017 deltaDOT are launching a new series of articles dD Techniques on the  capabilities of their High Performance Label Free Imaging Capillary Electrophoresis technology.  The articles offer accessible information and an insight into this unique technology which is used  worldwide to solve challenging analytical problems. A new perspective on the tools required for  the development and manufacture of monoclonal antibodies, biosimilars, stratified therapies,  viral vaccines and gene therapy vectors highlights the need for new analytical techniques.  These new perspectives are the aims which dD Techniques articles intend to deliver to a wide  range of audience (...links to article1, article2, article3)  24 August 2017 The Technology partnership publication (www.ttp.com) now includes key facts  and data on deltaDOT’s High Precision Capillary Electrophoresis advanced technology. The TTP  Journal of Technology and Business Innovation provides technical insight into UK advanced  scientific businesses (...more) 3rd July 2017 Future Targeted Healthcare Manufacturing. deltaDOT announce their  participation in the new EPSRC funded Future Targeted Healthcare Manufacturing Hub, led by  UCL (...more). The Hub will address the manufacturing, business and regulatory challenges to  ensure that new targeted biological medicines can be developed quickly and manufactured at  affordable costs (...more).   24th January 2017 – deltaDOT Ltd. announces compliance with CFR 21 part 11 of USA’s Food  and Drug Administration. deltaDOT now offers an upgraded version of its control and analysis  software which has been designed to aid users of deltaDOT’s HPCE-512 Hig Performance  Capillary Electrophoresis instrument in achieving compliance with CFR 21 part 11.The upgrade  package contains controls to help meet the stringent requirements of CFR 21 part 11 including  the system access by authorised personel only, maintaining audit trails of user actions,  generating complete and protected data files and the application of electronic signatures to data  (...more)  20 Sep 2016 National Health Service Quality Control North West (QCNW) Liverpool  labs  presented the data on monoclonal antibody stability trials based on deltaDOT’s Capillary  Electrophoresis (CE) technology  and expertise. They state that CE technology is suitable for  monitoring the stability of monoclonal antibodies and can perform purity and charge analysis with  high resolution and repeatability. They conclude that CE can replace other techniques commonly  used for this analysis IEC and SDS PAGE (link to the poster).  3rd July 2016 Monoclonal Antibody Stability Trials using deltaDOT HPCE-512 technology  reported by Dr. Deepika Devanur. Now available in pdf slide format on our website (...more)  4th March 2016, FDA CFR21/11 Compliance - deltaDOT’s progress continues with the  implementation of the software quality system while the P3 controller system management  software and the P3EVA analysis package had their compliance completed previously deltaDOT  engineers are working with Optra systems of California (...more)  26th January 2016, National Health Service Quality Control North West (QCNW) Liverpool  Labs are to perform monoclonal antibody stability trials, utilising deltaDOT Ltd. technology and  expertise to aid the study.     4th February 2016 Webinar: Improve your Monoclonal Antibodies Analysis. Live webinar on  analysing mAbs from production to patient. Given jointly by Horiba Scientific and deltaDOT Ltd.  Presented by Dr. Deepika Devanur (...registration site)